Deciphera Pharmaceuticals Closes $75M Series B Financing
September 22, 2015
Clinical stage biotech Deciphera Pharmaceuticals has closed a $75 million Series B financing led by New Leaf Venture Partners. The company, which focuses on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, plans to use a portion of the proceeds from the fundraise to advance two of its lead candidates through clinical proof-of-concept. As part of the financing, New Leaf managing director Liam Ratcliffe will be joining the Board of Directors.